Peptide Initiative

Peptide profile · Immune

Nisin

FDA GRAS-approved lantibiotic (34 amino acids) produced by Lactococcus lactis with a dual antimicrobial mechanism — binds lipid II to block cell wall synthesis AND forms 2 nm transmembrane pores for rapid bacterial killing at MIC 0.5-4 μg/mL against gram-positive pathogens including MRSA and Listeria monocytogenes — the only antimicrobial peptide with over 50 years of documented safe human consumption

Strong human trialsNot an FDA-approved drug
Rapidly degraded in GI tract by digestive proteases; stable for hours to days in food matrices at acidic pH; lanthionine ring structures resist most environmental proteases; thermostableHalf-life (survives pasteurization)
Degraded by pancreatic proteases in GI tractBioavailability (does not affect gut microbiome at dietary levels); topical application achieves effective local concentrations; optimal activity at pH 2-6; lanthionine bridges provide significant protease resistance compared to linear peptides
3,354.12Molecular weight, Da

Molecular formula

C143H230N42O37S7

CAS number
1414-45-5
PubChem
16129667
Developed · 1928 (discovery); 1947 (naming and characterization); 1969 (first food use approval, UK); 1988 (FDA GRAS status, USA); ongoing therapeutic research
Lactococcus lactis (natural source); Danisco/Dupont, Danisco / DuPont Nutrition & Health

Amino acid sequence

Ile-Dhb-Ala-Ile-Dha-Leu-Ala-Abu-Pro-Gly-Ala-Lys-Abu-Gly-Ala-Leu-Met-Gly-Ala-Asn-Met-Lys-Abu-Ala-Abu-Ala-His-Ala-Ser-Ile-His-Val-Dha-Lys (34 amino acids, 5 lanthionine/methyl-lanthionine ring bridges A-E, contains dehydroalanine (Dha), dehydrobutyrine (Dhb), and aminobutyric acid (Abu) from post-translational modification)

ImmuneNisin provides potent antimicrobial activity through its unique dual mechanism: binding lipid II blocks cell wall synthesis (like vancomycin) while simultaneously using the lipid II-nisin complex to form 2 nm transmembrane pores for rapid bacterial lysis — this two-pronged killing mechanism at MIC 0.5-4 μg/mL makes resistance development extremely difficult and has maintained efficacy across 50+ years of use

0.9

Healing & RecoveryEmerging topical wound care applications exploit nisin's potent anti-gram-positive and anti-biofilm activity, with lanthionine-stabilized structure providing protease resistance in wound environments — veterinary mastitis treatment demonstrates clinical antimicrobial efficacy, supporting translation to human wound care

0.7

Anti-AgingPotential anticancer activity (IC50 11.68 μg/mL against MCF-7 breast cancer cells ) through selective membrane disruption of cancer cells, combined with immunomodulatory properties and the safety profile of 50+ years of human dietary consumption, positions nisin as an emerging geroprotective research compound

0.5

Ratings out of 10.

10 – 50mcg

Every documented dose level

PhaseDoseFrequency
Weeks 1-410-50 mcg/mL applied to the affected areaOnce or twice daily
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for food preservation as a natural antimicrobial alternative to chemical preservatives & research into novel antimicrobial therapeutics based on lantibiotic scaffolds

Best for

  • Food preservation as a natural antimicrobial alternative to chemical preservatives

    Nisin is particularly well-suited for individuals focused on food preservation as a natural antimicrobial alternative to chemical preservatives. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Research into novel antimicrobial therapeutics based on lantibiotic scaffolds

    Nisin is particularly well-suited for individuals focused on research into novel antimicrobial therapeutics based on lantibiotic scaffolds. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Anti-Listeria and anti-Clostridium strategies in food safety and clinical settings

    Nisin is particularly well-suited for individuals focused on anti-listeria and anti-clostridium strategies in food safety and clinical settings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Development of antimicrobial wound dressings and dental applications

    Nisin is particularly well-suited for individuals focused on development of antimicrobial wound dressings and dental applications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for immune supportConsult your healthcare provider for alternatives to Nisin based on your specific needs and medical history
Alternative immune-modulating peptidesThymosin Alpha-1LL-37Thymulin
Non-peptide immune supportVitamin D3Zinc supplementationBeta-glucans

Do not use if

  • Known hypersensitivity to nisin or Lactococcus lactis-derived products
  • Milk protein allergy — nisin production involves dairy-associated bacteria and preparations may contain trace milk proteins
  • Pregnancy and breastfeeding at therapeutic (non-dietary) doses — standard dietary exposure through preserved foods is considered safe
  • Active inflammatory bowel disease — potential for local irritation at high oral concentrations exceeding normal dietary levels

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Nisin use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Nisin with similar peptides to find the best fit for your goals.

Route

Nisin is administered Oral (food-grade preservative, GRAS)—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

The Nisin dosing protocol covers how it is taken.

3 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Nisin holds FDA GRAS status since 1988 with over 50 years of documented safe human consumption, making it the only antimicrobial peptide with this comprehensive long-term safety record.

Oral LD50 of 174 mg/kg in mice (comparable to table salt) demonstrates extraordinary safety margin. Acceptable daily intake established at 0.13 mg/kg body weight with no reported serious adverse events at this or higher levels.

Primary risk is milk protein contamination during production, requiring screening for lactose-intolerant or milk-allergic individuals.

FDA GRAS designation based on 50+ years of food-industry safety data with millions of exposed consumers globally. Bacterial production method prevents synthetic impurities; stability through pasteurization and food processing verified via microbiological and mass spectrometry analysis.

Animal toxicity studies and human safety monitoring across multiple continents show no systemic toxicity, genotoxicity, or carcinogenic potential. European Food Safety Authority also designated as safe food additive (E234).


Common side effects · experienced by some users

No significant effects at dietary levels

At FDA GRAS concentrations used in food preservation (ADI 0.13 mg/kg BW), nisin has no documented side effects across 50+ years of global dietary consumption by millions of people.

Management
No management needed. Nisin at dietary levels is one of the most well-documented safe food additives in history.

Mild GI discomfort at research doses

At oral doses significantly exceeding normal dietary exposure in research settings, mild gastrointestinal discomfort (nausea, mild cramping) may occur.

Management
Take with food. Reduce dose if symptoms persist. GI effects are typically transient and dose-dependent.

Local irritation (topical use)

Mild local irritation, redness, or warmth at topical application sites in wound care or dental research settings.

Management
Generally self-limiting. Reduce concentration if irritation is excessive. Nisin is most stable and active at acidic pH, which may contribute to local irritation.

Serious side effects

No documented serious adverse effects

No serious adverse effects documented across 50+ years of global food use. Oral LD50 in mice is 174 mg/kg, comparable to table salt (3,000 mg/kg for NaCl). The therapeutic index for antimicrobial activity is extraordinarily wide.

Management
Continue monitoring in novel therapeutic applications. The extensive food safety record provides strong reassurance, though clinical trial data for non-food therapeutic uses is still developing.

Less commonMilk protein allergic reactionGram-negative overgrowth

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Nisin
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Nisin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeEDTA (chelating agent) — EDTA disrupts the gram-negative outer membrane barrier, allowing nisin access to lipid II and extending activity to gram-negative pathogens including E. coli and Pseudomonas — May be used together under medical guidance.
  • SafePolymyxin B — synergistic combination where polymyxin disrupts gram-negative outer membranes while nisin targets the exposed cytoplasmic membrane lipid II, providing broad-spectrum coverage — May be used together under medical guidance.
  • SafeOrganic acids (citric acid, lactic acid) — enhance nisin stability and activity at acidic pH while providing complementary antimicrobial effects for food preservation — May be used together under medical guidance.

With medications

  • CautionAlkaline formulations (pH >7) — nisin activity and stability decrease significantly above neutral pH, with degradation accelerating at alkaline conditions — Use with caution—discuss with your healthcare provider.
  • CautionProteolytic enzymes (trypsin, chymotrypsin at high concentrations) — while lanthionine bridges provide some resistance, extensive proteolysis can reduce activity — Use with caution—discuss with your healthcare provider.
  • CautionHigh-fat food matrices without emulsification — nisin may partition into fat phase, reducing aqueous concentration and antimicrobial activity — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Nisin. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs minutes to hours (antimicrobial action)

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

Not an FDA-approved drug

Nisin preparation is affirmed as GRAS (21 CFR 184.1538, 1988) only as a food antimicrobial, for example to inhibit Clostridium botulinum in pasteurized cheese spreads; therapeutic uses are investigational.

Onset of effects

Rapid

(hours to days)


How it works

Nisin is a lantibiotic (modified antimicrobial peptide) produced by beneficial bacteria that kills harmful bacteria by disrupting cell membranes and is widely used as a natural food preservative.

The deeper mechanism

Nisin is a 34-amino acid lantibiotic produced by Lactococcus lactis containing post-translationally modified amino acids including lanthionine, methyl-lanthionine, and unusual ring structures (A, B, C, D, E rings).

These modifications create a rigid, protease-resistant structure enabling oral bioavailability.

Nisin exhibits bactericidal activity through dual mechanisms: (1) forming nisin-lipid II complexes on bacterial cell membranes, blocking peptidoglycan synthesis; and (2) direct membrane permeabilization via pore formation.

This dual-action mechanism provides resistance to nisin-resistant mutants compared to single-target antibiotics, making it particularly valuable as a food-grade antimicrobial and anti-biofilm agent.


What to expect

  1. Minutes to hours (antimicrobial action)

    What you might notice

    • Rapid bactericidal activity through dual lipid II binding and pore formation
    • Bacterial killing begins within minutes of exposure at MIC concentrations
    • In food applications, immediate preservation effect upon incorporation
    • In topical research, rapid reduction in gram-positive bacterial counts

    What's normal

    • Nisin's pore-forming mechanism causes extremely rapid bacterial killing (minutes)
    • The dual mechanism (cell wall + membrane) means even partially resistant bacteria are killed
    • Activity is optimal at acidic pH (2-6) and decreases at neutral-alkaline conditions

    What's next

    • For food preservation: nisin provides ongoing protection throughout shelf life
    • For research applications: monitor antimicrobial efficacy through culture assays
    • Consider gram-negative coverage needs (add EDTA or polymyxin if required)
  2. Days 1-7 (research or therapeutic application)

    What you might notice

    • Significant reduction in gram-positive pathogen burden at treatment site
    • Improved wound bed quality in topical antimicrobial research models
    • Spore outgrowth inhibition maintaining protection against Clostridium and Bacillus
    • Stable antimicrobial activity maintained by lanthionine-stabilized peptide structure

    What's normal

    • Nisin's lanthionine bridges provide exceptional protease resistance at wound sites
    • Continuous antimicrobial pressure prevents recolonization of treated surfaces
    • pH of wound environment affects efficacy — optimal in slightly acidic conditions

    What's next

    • Continue application per research protocol
    • Assess need for combination agents if gram-negative organisms are present
    • Monitor for any microbiome shifts in extended topical use
  3. Week 2-8 (extended application)

    What you might notice

    • Sustained antimicrobial protection without evidence of resistance development
    • In wound models, progressive healing with reduced bacterial bioburden
    • In food applications, maintained preservation throughout product shelf life
    • Minimal resistance development reflecting nisin's 50+ year track record

    What's normal

    • Nisin's dual mechanism makes resistance development extremely difficult
    • Extended use safety is supported by decades of dietary consumption data
    • Lanthionine-stabilized structure maintains peptide integrity over weeks

    What's next

    • Complete research protocol endpoints
    • Document antimicrobial efficacy and any resistance monitoring data
    • Assess potential for clinical translation from food-grade to therapeutic-grade applications

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Nisin over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

What is nisin and why is it called a lantibiotic?

Nisin is a 34-amino acid antimicrobial peptide produced by the bacterium Lactococcus lactis. It is called a 'lantibiotic' (lanthionine-containing antibiotic) because it contains unusual amino acids — lanthionine and methyl-lanthionine — that are created by post-translational modification of the ribosomal peptide. These unusual amino acids form five thioether ring bridges (rings A-E) that give nisin its characteristic polycyclic structure, exceptional stability against heat and proteases, and its unique ability to bind lipid II. First discovered in 1928 by Rogers and Whittier at the USDA, nisin was named in 1947 and has been used in food preservation for over 50 years.

How does nisin's dual mechanism work?

Nisin kills bacteria through two simultaneous mechanisms. First, its N-terminal lanthionine rings (A and B) bind with high affinity to lipid II, the essential membrane-anchored precursor for cell wall synthesis. This alone blocks peptidoglycan construction, similar to vancomycin. Second, the bound lipid II-nisin complex then serves as a docking molecule — nisin's C-terminal region inserts into the membrane using lipid II as an anchor, forming 2 nm pores made of approximately 8 nisin and 4 lipid II molecules. These pores cause rapid ion leakage, ATP loss, and membrane depolarization. This dual pathway means bacteria would need to simultaneously develop resistance to both mechanisms — explaining why significant resistance has not emerged despite 50+ years of use.

Is nisin safe for human consumption?

Nisin has one of the strongest safety records of any antimicrobial agent. It received FDA GRAS (Generally Recognized As Safe) status in 1988 and is approved as food additive E234 in over 50 countries. The Joint FAO/WHO Expert Committee established an ADI (Acceptable Daily Intake) of 0.13 mg/kg body weight. The oral LD50 in mice is 174 mg/kg — comparable to table salt. Importantly, nisin is rapidly degraded by digestive enzymes (pancreatic proteases) in the human GI tract, meaning it does not accumulate or affect the normal gut microbiome at dietary levels. No adverse effects have been documented across decades of global food use.

Why doesn't nisin work against gram-negative bacteria?

Gram-negative bacteria have an additional outer membrane that gram-positive bacteria lack. This outer membrane acts as a physical barrier preventing nisin from reaching its target — lipid II in the cytoplasmic membrane. However, this limitation can be overcome by combining nisin with outer membrane-disrupting agents: EDTA chelates divalent cations that stabilize the outer membrane, and polymyxin directly disrupts the outer membrane lipid structure. Both combinations effectively extend nisin's activity to gram-negative pathogens including E. coli and Pseudomonas.

Can nisin be used to treat infections in humans?

While nisin is currently approved only for food preservation, there is growing research interest in therapeutic applications. It has shown efficacy in veterinary mastitis treatment (intramammary infusion), topical wound care research, dental applications (anti-plaque, anti-periodontal disease), and even anticancer research (selective cytotoxicity against cancer cells). Its extraordinary safety profile from 50+ years of dietary use provides a strong foundation for clinical development. However, formal human clinical trials for therapeutic indications are still in early stages, and nisin is not currently approved for clinical antimicrobial use.

How does nisin compare to vancomycin?

Both nisin and vancomycin target lipid II, the essential cell wall precursor, but their mechanisms differ significantly. Vancomycin binds the D-Ala-D-Ala terminus of lipid II's peptide chain, blocking transpeptidation. Nisin binds the pyrophosphate region of lipid II using its lanthionine rings, then additionally forms membrane pores — a second killing mechanism that vancomycin lacks. This dual mechanism makes nisin effective against some vancomycin-resistant organisms. However, vancomycin is established for systemic IV therapy while nisin's clinical use is limited to food preservation and topical research applications due to its peptide nature and pharmacokinetic limitations.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Nisin, on one page.

Nisin dosing protocol

Medical disclaimer

Nisin is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

10 – 50 mcg Once or twice daily · onset hours to days
Open the Nisin calculatorNisin calculator